Illumina, Inc. (ILMN)
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago.
Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Here's Why Illumina (ILMN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
Does Illumina (ILMN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?
ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat
Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow. NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue?
Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Continue to Hold ILMN Stock in Your Portfolio?
Illumina builds on strong NovaSeq X demand and clinical sequencing momentum, but China weakness and cost pressures keep challenges in focus.
Here's Why Illumina (ILMN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
